Last updated: July 25, 2026
ecutive summary:
Horizon Pharma USA, Inc. v. Actavis Laboratories UT, Inc. (No. 1:16-cv-05051) is a US patent-infringement dispute tied to the Hatch-Waxman Paragraph IV framework. The case footprint is limited in the public docket record. No patent numbers, asserted claims, product details, or claim-construction outcomes are available from the provided case identifier alone, so a litigation summary with actionable conclusions on infringement/validity, settlement posture, or generic launch timing cannot be produced.
Horizon Pharma USA v. Actavis Laboratories UT 1:16-cv-05051: What patents were asserted and what claims were litigated?
A complete litigation summary requires identifying (i) the asserted patent numbers, (ii) the asserted claims, and (iii) the accused Actavis product and regulatory filing. The case identifier “1:16-cv-05051” does not include these specifics.
What patents were at issue in 1:16-cv-05051?
A litigation analysis must list each asserted US patent (publication and patent number), the assignee(s), filing date, and expiration and regulatory carveouts. That information is not available from the provided input.
What drug product and Orange Book reference listed patents were implicated?
Paragraph IV cases connect to an FDA application and a specific Orange Book drug product with listed patents (drug substance, drug product, and method-of-use). The dossier required to map 1:16-cv-05051 to a particular Orange Book listing is not present.
What did the pleadings allege (infringement theory and validity defenses)?
A credible analysis requires the infringement claim chart theory (direct, induced, contributory) and the validity posture (anticipation, obviousness, §101, §112, inequitable conduct). No docket text is provided.
What happened procedurally in Horizon v. Actavis (1:16-cv-05051): motion practice, hearings, and rulings?
A procedural timeline is needed: deadlines, Markman schedule, summary judgment motions, Daubert challenges, and trial or dismissal events. The provided input does not include any docket entries.
Timeline checkpoints that define litigation posture
- complaint and service
- responsive pleading
- claim construction (Markman)
- dispositive motions
- final judgment or dismissal
- any stay and lifting events
None of these events are supplied in the prompt.
Were there claim-construction or summary-judgment outcomes?
Without docket rulings, there is no basis to state whether the court construed key terms against or for Horizon, ruled on anticipation/obviousness, or narrowed asserted claims.
Did the parties settle, and did the settlement delay generic entry?
Paragraph IV cases commonly end via settlement or consent judgments that specify an effective date for generic launch or design-around requirements. Settlement terms drive downstream market exclusivity and non-infringement risk.
Were there consent judgments or stipulated dismissals?
No settlement or dismissal details are provided.
Did any launch date or “carve-out” enter the record?
Launch timing requires an agreement date and an “allowable” launch date tied to FDA approval and patent expiry. That information is missing.
How do Paragraph IV and Hatch-Waxman exclusivity timelines affect generic launch risk here?
A risk analysis requires connecting the case to:
- the reference listed drug (RLD)
- the ANDA (or other FDA filing)
- the Orange Book listed patents
- the relevant statutory exclusivity periods
- the date(s) of FDA approval and any 30-month stay expiration
No RLD/ANDA mapping is available.
What defenses could Actavis have raised, and how strong were they based on court decisions?
To assess strength, an analyst must cite:
- specific invalidity arguments and the court’s treatment
- surviving claims after claim construction
- evidentiary rulings
- any final judgment on infringement and validity
No such content is available.
What generic entry risks exist for Actavis and competitors if the court ruled against Horizon (or upheld Horizon’s patents)?
A launch risk assessment depends on case outcome (infringement and/or validity). Without the judgment status, infringement probability cannot be stated.
Scenario mapping by outcome
- If Horizon won on infringement and validity: generic entry is blocked until expiration or design-around clearance.
- If Horizon lost on validity or non-infringement: other Paragraph IV challengers face reduced injunction risk.
No outcome data is provided.
How does this case compare with other Horizon Pharma v. generic litigation involving Actavis or similar challengers?
Comparative analysis requires:
- docket outcomes in other Horizon cases
- common asserted patents and claim scopes
- recurring manufacturing or formulation workarounds
No cross-case list is included.
Key Takeaways
- The case identifier alone is insufficient to produce a litigation summary that includes asserted patents, accused product details, procedural milestones, rulings, or settlement/launch implications.
- No court outcome, claim construction result, or final disposition can be stated from the provided input.
FAQs
- What is the Orange Book patent mapping for Horizon v. Actavis (1:16-cv-05051)?
- Which specific patents and claims did Horizon assert against Actavis in 1:16-cv-05051?
- What was the case outcome in Horizon Pharma USA v. Actavis Laboratories UT?
- Did the court issue an injunction or did the parties enter a settlement in 1:16-cv-05051?
- How does the 30-month stay and any later settlement affect FDA approval timing for Actavis in this matter?
References
- Not provided in the prompt.
